Zimmer Biomet Holdings stock: Undervalued at $91 with 13% upside potential?

Zimmer Biomet Holdings trades at $91.40, 13% below analyst targets amid strong Q4 results and robotics growth—could this medtech leader offer value for your portfolio? Investors worldwide eye its orthopedic dominance and margin gains. ISIN: US98956P1021

You’re looking at Zimmer Biomet Holdings, a powerhouse in orthopedic implants and surgical tech, trading on the NYSE under ZBH in USD. With shares around $91.40 as recent data shows, the stock sits modestly below analyst targets, sparking questions on whether it's a buy now amid steady demand for knee and hip replacements.

As of: 08.04.2026

By Elena Voss, Senior Medtech Analyst: Zimmer Biomet leads in reconstructive implants, powering healthier lives through innovative orthopedics in a sector ripe for digital transformation.

What Zimmer Biomet Does and Why It Matters

Zimmer Biomet Holdings designs, manufactures, and sells orthopedic reconstruction implants, traumatology products, and surgical tools. You know the core: knee and hip replacements make up the bulk, about 67% of sales, with knees leading at over 60% of that segment. This isn't just hardware; it's about restoring mobility for millions facing joint issues as populations age globally.

The company operates in a massive market where demand surges from rising orthopedic procedures. In the U.S., Europe, and beyond, aging demographics mean more patients needing these solutions. Zimmer Biomet reported Q4 revenue of $2.24 billion, up 10.9% year-over-year, beating estimates by $20 million, with EPS at $2.42 versus $2.38 expected. That's execution you can bank on.

For you as an investor, this translates to resilience. The firm guides FY2026 EPS at $8.30-$8.45, ahead of the $8.22 consensus, signaling confidence in sustained growth. Whether you're in New York, London, or Sydney, this stock offers exposure to a defensive healthcare play with global reach.

Recent Performance and Market Position

Shares opened around $91.38 recently, with a 50-day moving average of $92.51 and 200-day at levels supporting stability. The 52-week range spans $84.59 to $108.29, showing volatility but a low beta of 0.61 means less market swing than peers. Market cap hovers near $17.69 billion, with P/E at 25.81 and PEG of 1.86—reasonable for growth medtech.

Over the past year, returns mixed: down about 10% but with short-term gains of 0.44% daily and 1.08% weekly. This dip positions it 13% below mean targets around $102-$106, per consensus from 27 analysts rating it Hold/Outperform. You see undervaluation signals, like fair value estimates at $103.

Zimmer Biomet's edge comes from premium products driving margins. Net margin at 8.56%, ROE 12.93%—solid fundamentals amid industry tailwinds like robotics adoption. For global investors, this means steady dividends too: $0.24 quarterly, yielding about 1.1%.

Innovation Driving Future Growth

You're investing in more than implants; Zimmer Biomet pushes digital health, robotics, and data platforms like ROSA and upcoming Monogram. These boost premium product adoption, mix shift, and recurring revenue from connected ecosystems. Margins expand as surgeons opt for high-tech solutions.

The U.S. core business remains pivotal, but international expansion adds layers. With revenue growth outpacing estimates, guidance reflects bets on these innovations. You benefit from predictable earnings in a sector where procedure volumes climb steadily.

Competitors like Stryker or Globus Medical watch closely, but Zimmer's scale in knees and hips gives moat. Recent stake builds by investors like Oak Thistle LLC, up 78.8% to $2.636 million, signal confidence. This isn't hype—it's validated demand.

Analyst Views on Zimmer Biomet

Analysts lean cautiously optimistic on Zimmer Biomet. Consensus from 27 firms points to Outperform/Hold, with average targets around $102.30-$106.20, implying 12-13% upside from $91.40 levels. FactSet polls show this spread, balancing growth prospects against execution risks.

Goldman Sachs recently nudged its target to $89 from $88, holding Sell— a bearish outlier amid broader positivity. Simply Wall St's fair value model pegs $103, citing undervaluation tied to digital investments. MarketBeat tracks mixed individual views from Strong Buy to Sell, but group EPS forecasts align near $8.22.

For you, this mosaic means weighing upgrades in robotics against any procedural slowdowns. Reputable houses focus on margin expansion and U.S. strength. No single view dominates, but the tilt toward upside rewards patient investors.

Why This Matters to You as an Investor

Whether U.S., European, or global, Zimmer Biomet fits defensive portfolios. Healthcare spending rises universally, with orthopedics recession-resistant. You get dividend stability plus growth from tech infusions—ideal for long-term holds.

Current pricing offers entry below targets, post-mixed returns. Q4 beats and FY2026 guidance underscore reliability. Track earnings on May 4, 2026, for Q1 updates confirming trajectory. This stock rewards those eyeing undervalued medtech leaders.

Global relevance shines: procedures transcend borders, and currency-hedged exposure via NYSE suits diverse portfolios. Your watchlist gains a steady performer with innovation upside.

Risks and What to Watch Next

No stock's risk-free, and Zimmer Biomet faces procedural volume fluctuations or reimbursement pressures. If elective surgeries dip, as in past downturns, revenue could soften. Competitive robotics race demands flawless execution.

Supply chain hiccups or regulatory hurdles in new platforms like Monogram loom. Valuation at 45% intrinsic discount tempts, but mixed analyst tones urge caution—Goldman's Sell highlights execution worries. Monitor beta for broader market ties.

What should you watch? Q1 earnings May 4, 2026, guidance updates, and robotics adoption metrics. Dividend continuity and stake changes like Oak Thistle's signal sentiment. Globally, track U.S. Medicare shifts impacting volumes.

Should You Buy Zimmer Biomet Now?

Buy? If you seek undervalued medtech with beats, guidance beats, and robotics catalysts, yes—13% upside beckons patient holders. Hold if execution risks weigh heavy; consensus tilts positive but mixed.

This stock suits diversified portfolios chasing healthcare stability. Weigh your risk tolerance against tailwinds like aging populations. Stay informed on earnings and innovations—your edge in deciding.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.